Zacks Investment Research notes that EndoChoice has been assigned a consensus broker rating score of 1.00 — strong buy — from the four brokers that provide coverage for the company, according to a Dakota Financial News report.
Here are four quick facts:
1. Brokers have set a one-year consensus target price of $23.33 for the company.
2. EndoChoice has a one-year low of $14.26 and a one-year high of $19.69.
3. The stock's 50 day moving average is $16.13 and its 200-day moving average is $16.25.
4. The firm's market cap is $414.19 million.